Coherus BioSciences Sees FY24 R&D And SG&A Expenses $250M-$265M
Portfolio Pulse from Benzinga Newsdesk
Coherus BioSciences projects its FY24 R&D and SG&A expenses to be between $250 million and $265 million.
August 08, 2024 | 9:10 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Coherus BioSciences has announced that its FY24 R&D and SG&A expenses are expected to be between $250 million and $265 million.
The announcement of projected expenses provides investors with insight into the company's financial planning and resource allocation. However, it does not directly indicate a significant positive or negative impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100